ReviewDrugs & aging2002
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
Review in Drugs & aging, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.European journal of clinical pharmacology · 2018Pooled it
- Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.Journal of geriatric oncology · 2021Trial
- Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics.Discover oncology · 2025Review
- Article
- Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2015Article
- Optimal management of breast cancer in the elderly patient: current perspectives.Clinical interventions in aging · 2015Review
- Prescribing oral chemotherapy.BMJ (Clinical research ed.) · 2007Article
- Oral anticancer drugs in the elderly: an overview.Drugs & aging · 2007Review
- Pharmacokinetic optimisation of treatment with oral etoposide.Clinical pharmacokinetics · 2004Review
- Pharmacological factors influencing anticancer drug selection in the elderly.Drugs & aging · 2003Review
- Pharmacology of anticancer drugs in the elderly population.Clinical pharmacokinetics · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persons over the age of 65 years are the fastest growing segment of the US population. In the next 30 years they will comprise over 20% of the population. Fifty per cent of all cancers occur in this age group and therefore there will be an expected rise in the total cancer burden. There has been an increasing trend over the past 20 years toward the use of oral chemotherapy. This change has been encouraged by the need to decrease the costs of chemotherapy administration, patient preferences and quality of life issues. Factors that must be considered with oral chemotherapy administration include limitations of saturability of absorption, patient compliance and pharmacokinetic/pharmacodynamic changes which occur in elderly patients. Interpatient variability and drug metabolism, particularly age-related changes in drug metabolism are being studied. The cytochrome P450 system has been intensively studied because of its importance with regard to chemotherapeutic drugs. This article reviews these issues and provides details regarding specific drugs including temozolomide, thalidomide, topotecan, the fluoropyrimidines, etoposide, hydroxycarbamide (hydroxyurea), tamoxifen, and alkylating drugs. Complementary and alternative therapies are also discussed.
Indexed as
Identifiers
11929325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.